丁酰胆碱酯酶通过旁分泌毒蕈碱信号缓解肝星状细胞活化
本研究探讨丁酰胆碱酯酶(BuChE)是否通过调节乙酰胆碱(ACh)生物利用度调控肝纤维化。在患者活检及多种小鼠模型中,BuChE表达和血清活性在纤维化时显著下调,且与F分期和α-SMA表达负相关。肝细胞BuChE缺失或抑制促进HSC活化和纤维化,而过表达具保护作用;机制上,BuChE缺失导致ACh积聚,通过ChRM3-NF-κB信号激活HSC。
要点
- BuChE在纤维化肝中表达和活性下调,与纤维化分期负相关。
- 肝细胞BuChE缺失或抑制加重HSC活化和纤维化,过表达则保护。
- BuChE缺失致ACh积聚,经ChRM3-NF-κB信号激活HSC驱动纤维化。
核心结论
- 肝细胞损伤破坏BuChE活性,导致局部ACh积聚,通过ChRM3信号激活HSC,驱动纤维化,该胆碱能环路是可干预的治疗靶点。
研究设计与样本
- 在患者活检中通过qPCR和免疫染色评估BuChE表达,并利用Buche ΔHep小鼠、Buche KI/KI-Hep小鼠、药理抑制、突变BuChE条件培养基和重组蛋白进行研究。
- 采用膜片钳和钙动员实验测量ACh释放和毒蕈碱乙酰胆碱受体(ChRM)功能,并通过Chrm3 ΔHSC小鼠和AAV6介导的过表达测试ChRM3作用。
主要发现
- 纤维化患者和小鼠中BUCHE mRNA和血清活性显著下调,与F分期和α-平滑肌肌动蛋白表达呈负相关。
- BuChE主要在肝细胞表达,TGF-β或PDGF处理可降低其表达,其抗纤维化功能依赖酶活性。
- 肝细胞BuChE缺失或抑制在多个模型中增加HSC活化和纤维化,而过表达具保护作用,确立因果关系。
- BuChE缺失导致未代谢ACh积聚,作为损伤相关分子模式信号通过ChRM3-NF-κB信号激活HSC。
- Chrm3 ΔHSC小鼠显示HSC活化和纤维化减轻,而Chrm3过表达促进纤维化。
临床怎么用
- BuChE活性或可作为肝纤维化的负相关标志物,但需进一步验证。
- 靶向肝细胞BuChE或ChRM3信号通路可能成为抗纤维化治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Butyrylcholinesterase (BuChE) is a metabolic enzyme implicated in Alzheimer's disease, detoxification and depression. Although reduced BuChE expression is recognised in cirrhosis, its functional role in fibrogenesis remains undefined. OBJECTIVE: We investigated whether BuChE regulates fibrosis by modulating acetylcholine (ACh) bioavailability and identified downstream cholinergic signalling. DESIGN: BuChE expression was assessed via qPCR and immunostaining in patient biopsies. Its contribution was studied using Buche ΔHep, Buche KI/KI-Hep mice, pharmacological inhibition, mutant BuChE conditioned medium and recombinant protein. ACh release and muscarinic ACh receptor (ChRM) function were measured using patch-clamp and calcium mobilisation assay; ChRM3 role was tested via Chrm3 ΔHSC mice and AAV6-mediated overexpression. RESULTS: BUCHE mRNA and serum activity are significantly downregulated in fibrotic patients and mice, correlating negatively with F stage and alpha-smooth muscle actin expression. BuChE is predominantly expressed in hepatocytes in the liver, which can be reduced by transforming growth factor beta or platelet-derived growth factor treatment, and its anti-fibrotic function requires enzymatic activity. Hepatocyte BuChE deletion or inhibition increases hepatic stellate cell (HSC) activation and fibrosis across multiple models, whereas overexpression is protective, establishing causality. Loss of BuChE leads to accumulation of unmetabolised ACh, which activates HSCs as a damage associated molecular pattern signal via ChRM3-NF-κB signalling. Chrm3 ΔHSC mice exhibit attenuated HSC activation and fibrosis, whereas Chrm3 overexpression promotes fibrogenesis. CONCLUSION: Hepatocyte injury disrupts BuChE activity, causing local ACh accumulation and subsequent HSC activation via ChRM3 signalling. This newly identified cholinergic circuit drives fibrosis and represents a druggable target for therapeutic intervention.
引用
- Tao L, Liu N, Zhang W, et al. Butyrylcholinesterase alleviates hepatic stellate cell activation via paracrine muscarinic signalling. Gut. 2026. PMID: 42778344. doi:10.1136/gutjnl-2026-338932
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。